The cancer drugmaker pled guilty of violating the Federal Food, Drug and Cosmetic Act by failing to provide certain records to investigators in federal court. 

Merck

Merck & Co. Inc. was in talks with governments and companies to potentially help with manufacturing of Covid-19 vaccines that have been already authorized.

AstraZeneca expects to produce more than 100 million doses of the company’s Covid-19 vaccine – developed with Oxford University – during February, ramping up to more than 200 million a month by April, Chief Executive Pascal Soriot said.

AbbVie announced the company’s latest chimeric antigen receptor (CAR)-T cell investment, a collaboration with Caribou Biosciences worth $40 million up front in cash and equity to develop two CRISPR-edited cell therapies against AbbVie-specified targets.

Belgo-Dutch biotech Galapagos NV and U.S. partner Gilead Sciences Inc. will discontinue late-stage trials testing their experimental drug ziritaxestat in patients with pulmonary fibrosis.

The program unites academia and industry, providing students with a real-world, skills-based education and direct connections to leaders in healthcare marketing and communications.

Johnson & Johnson Chief Executive Officer Alex Gorsky told CNBC that people may need to get vaccinated against Covid-19 annually over the next several years, like seasonal flu shots.

Basel-based Lonza AG is moving to sell the company’s Lonza Specialty Ingredients division to private equity firms Bain Capital and Cinven for CHF 4.2 billion ($4.7 billion), completing a planned pivot to focus on Lonza Pharma, Biotech & Nutrition business. 

Anat Ashkenazi was tapped to take over as chief financial officer of Eli Lilly following the abrupt resignation of Josh Smiley, who departed the company following allegations of an inappropriate relationship with an employee.

Committed to serving the COPD community, AstraZeneca’s BREZTRI team is unveiling their latest, direct-to-consumer US advertising campaign, “Get Real.”